Comparison

BPC-157 vs
KPV

Different molecules, different human evidence. In the US, both appear in the same draft compounding policy; in sport, the World Anti-Doping Agency names BPC-157; KPV is not named, and WADA says an unnamed peptide may still be prohibited.

Short answerCompound research · 5 min read · Updated 21 Nov 2026

BPC-157 is a synthetic 15-amino-acid peptide; KPV is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone. BPC-157 has small human studies and randomized data reported in conference abstracts. FDA staff found no clinical studies that gave KPV to people. The evidence does not support ranking the two.

Key takeaways

  • BPC-157 has limited human evidence, including randomized studies reported as conference abstracts, while FDA staff found no clinical studies that gave KPV to people.
  • The US Department of Health and Human Services names both peptides in its October 2026 draft compounding policy, which the Federal Register notice says is not binding.
  • WADA names BPC-157 in class S0 and prohibits it at all times; KPV is not named on the 2026 or 2027 List, but WADA warns that unnamed peptides may still be prohibited.

01BPC-157 vs KPV in one table

QuestionBPC-157KPV
IdentitySynthetic 15-amino-acid peptideThree-amino-acid peptide, lysine–proline–valine, from the sequence of alpha-melanocyte-stimulating hormone
Evidence tierMostly animal research (T3), with lab studies (T4) and limited human evidence (T2; randomized data in conference abstracts)Animal (T3) and lab studies (T4), not evidence of an effect in people
Human dataSmall studies and randomized data reported in conference abstracts; material sold online is not the material studiedFDA staff found no clinical studies that gave KPV to people in their July 2026 review
United StatesFDA staff found no approved drug containing it; named in the October 2026 HHS draft compounding policy, which is not bindingFDA staff found no approved drug containing it; named in the October 2026 HHS draft compounding policy, which is not binding
United KingdomMarketing authorisation not confirmed here; MHRA classifies finished products case by caseMarketing authorisation not confirmed here; MHRA classifies finished products case by case
AustraliaNamed in Schedule 4 and Appendix D, clause 5, of the October 2026 Poisons Standard; scheduling is not approvalThe TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” KPV has no entry by name in the October 2026 Poisons Standard. We draw no scheduling conclusion of our own.
SportWADA names BPC-157 in S0 on the 2026 and 2027 Lists; prohibited at all timesKPV is not named on either List, but WADA warns that unnamed peptides may still be prohibited

Status as of 21 November 2026. The 2027 World Anti-Doping Agency (WADA) List comes into force on 1 January 2027.

02What differs in the research?

If you searched “kpv vs bpc-157”, start with who or what was studied. A study in living participants is different from one in lab-grown human cells, even when both are described as using human material.

BPC-157 in people

FDA staff summarise a placebo-controlled study with 32 healthy participants randomised, reported in meeting abstracts in 2002 and 2003. The abstracts cover tolerability and how the compound was processed in the body. We found no full paper of the study. Material sold online is not the material studied.

BPC-157 in rats

Staresinic and colleagues studied rats with a surgically cut Achilles tendon in 2003 (T3). That design does not show an effect in people.

KPV in the lab

Dalmasso and colleagues studied KPV in cultured human intestinal and immune cells (T4) and in mouse models (T3) in a 2008 paper. Neither is evidence of an effect in people.

FDA staff also summarise a 2005 randomized, placebo-controlled BPC-157 study: 53 people were randomised and 46 completed it. That study is known from a meeting abstract too. Material sold online is not the material studied in either trial. The BPC-157 research guide separates those abstracts from the other human reports.

03What stayed the same in US policy?

Both peptides followed the same US compounding timeline. A category change, an advisory vote, and a draft enforcement policy are different actions.

  1. September 2023 to 22 April 2026Category 2

    HHS says both were in FDA’s Category 2 during this period. HHS says neither placement nor removal changed their status under section 503A.

  2. July 2026Advisory votes

    FDA drug-centre staff recommended against adding either peptide to the list of bulk ingredients for section 503A compounding. HHS records that the advisory committee voted in favour of listing both. The votes were recommendations.

  3. 30 October 2026Draft policy notice

    The Federal Register published notice of a draft HHS policy. It states that HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians in the circumstances specified. The notice says the draft is not binding. HHS names both peptides and specifies one listed active ingredient per preparation and a patient-specific prescription.

In the UK, the Medicines and Healthcare products Regulatory Agency assesses a finished product’s presentation and function case by case. In Australia, the Poisons Standard is a scheduling document, not a list of approved products. In sport, S0 covers pharmacological substances not addressed elsewhere on the List that have no current government approval for human therapeutic use.

04What we don’t know

  • How they compare in people. The studies described here do not compare the two peptides in people, so they do not support a ranking.
  • Their safety profiles in people. In July 2026, FDA staff found insufficient clinical safety information to characterise BPC-157’s safety profile and said potential human safety risks for KPV were unknown because they had identified no clinical studies or human exposure data.
  • What a particular vial contains. A name on a label or a purity percentage does not establish identity. The lab report needs to match the lot and show a separate identity result.

How the lab report distinguishes them. FDA staff give different molecular weights for the free bases: 1419.5 g/mol for BPC-157 and 342.43 g/mol for KPV. The expected result must match the chemical form being tested. For how to find the identity result and distinguish it from purity, see how to read a certificate of analysis (COA).

This is a plain-English summary of public documents and studies as of 21 November 2026, not legal or medical advice.

RefSources

  1. US Food and Drug Administration. BPC-157-related bulk drug substances. Advisory committee briefing, July 2026, pp. 9–14, 30, 40–43, 54–55. www.fda.gov/media/193343/download
  2. US Food and Drug Administration. KPV-related bulk drug substances. Advisory committee briefing, July 2026, pp. 7–10, 20–27 and 38; includes Dalmasso et al. (2008). www.fda.gov/media/193346/download
  3. US Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. Draft policy, October 2026; read on the Internet Archive capture of 15 Nov 2026, the newest readable one (hhs.gov refuses automated readers). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  4. Federal Register. Notice of availability for the draft HHS enforcement-discretion policy, FR Doc. 2026-22192. Notice, 30 October 2026. www.federalregister.gov/documents/2026/10/30/2026-22192/enfo…
  5. Medicines and Healthcare products Regulatory Agency. A guide to what is a medicinal product. Guidance Note 8, sections 2–4. assets.publishing.service.gov.uk/media/6a747082bde92a23046b2…
  6. Australian Federal Register of Legislation. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, F2026L01327. Schedule 4 and Appendix D, clause 5; full text checked 21 November 2026. www.legislation.gov.au/F2026L01327/asmade/2026-09-30/text/or…
  7. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 September 2026; read on the Internet Archive capture of 5 Nov 2026, the newest (tga.gov.au does not respond to automated readers). www.tga.gov.au/resources/explore-topic/peptide-products
  8. World Anti-Doping Agency. The 2026 Prohibited List. International Standard, section S0. www.wada-ama.org/sites/default/files/2025-09/2026list_en_fin…
  9. World Anti-Doping Agency. The 2027 Prohibited List. International Standard, section S0; in force 1 January 2027. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  10. World Anti-Doping Agency. Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List. Explanatory note, section S0. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Are BPC-157 and KPV the same peptide?

No. BPC-157 is a synthetic 15-amino-acid peptide. KPV has three amino acids: lysine, proline, and valine.

Do human cell studies count as human trials of KPV?

No. Experiments in cultured human cells are lab studies, not trials in people. FDA staff found no clinical studies that gave KPV to people in their July 2026 review.

What did the October 2026 HHS notice say about BPC-157 and KPV?

HHS named both in its draft policy on enforcement discretion for certain compounders under specified conditions. The Federal Register notice says the draft is not binding, and FDA staff found no approved drug containing either peptide.

What is the WADA status of BPC-157 and KPV?

WADA names BPC-157 in class S0 on the 2026 and 2027 Lists and prohibits it at all times. KPV is not named on either List, but WADA warns that unnamed peptides may still be prohibited.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page